289 related articles for article (PubMed ID: 21970456)
21. High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status.
Veluchamy JP; Heeren AM; Spanholtz J; van Eendenburg JD; Heideman DA; Kenter GG; Verheul HM; van der Vliet HJ; Jordanova ES; de Gruijl TD
Cancer Immunol Immunother; 2017 Jan; 66(1):51-61. PubMed ID: 27783105
[TBL] [Abstract][Full Text] [Related]
22. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL.
Cullup H; Hsu AK; Kassianos AJ; McDonald K; Radford KJ; Rice AM
J Immunother; 2011 May; 34(4):362-71. PubMed ID: 21499125
[TBL] [Abstract][Full Text] [Related]
23. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation.
Luevano M; Daryouzeh M; Alnabhan R; Querol S; Khakoo S; Madrigal A; Saudemont A
Hum Immunol; 2012 Mar; 73(3):248-57. PubMed ID: 22234167
[TBL] [Abstract][Full Text] [Related]
24. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
Condiotti R; Nagler A
Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
[TBL] [Abstract][Full Text] [Related]
25. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
[TBL] [Abstract][Full Text] [Related]
26. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.
Passweg JR; Koehl U; Uharek L; Meyer-Monard S; Tichelli A
Best Pract Res Clin Haematol; 2006; 19(4):811-24. PubMed ID: 16997185
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood.
Harris DT
Bone Marrow Transplant; 1995 Jan; 15(1):17-23. PubMed ID: 7742753
[TBL] [Abstract][Full Text] [Related]
28. Role of interleukin-15 in umbilical cord blood transplantation.
Lin SJ; Yan DC; Lee YC; Kuo ML
Int Rev Immunol; 2008; 27(6):518-31. PubMed ID: 19065354
[TBL] [Abstract][Full Text] [Related]
29. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.
St John LS; Wan L; He H; Garber HR; Clise-Dwyer K; Alatrash G; Rezvani K; Shpall EJ; Bollard CM; Ma Q; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):995-1001. PubMed ID: 27378343
[TBL] [Abstract][Full Text] [Related]
30. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Klingemann HG; Wong E; Maki G
Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
[TBL] [Abstract][Full Text] [Related]
31. Differential expansion of umbilical cord blood mononuclear cell-derived natural killer cells dependent on the dose of interleukin-15 with Flt3L.
Nagamura-Inoue T; Mori Y; Yizhou Z; Watanabe N; Takahashi TA
Exp Hematol; 2004 Feb; 32(2):202-9. PubMed ID: 15102482
[TBL] [Abstract][Full Text] [Related]
32. [Umbilical cord blood as a source of stem cells].
Bojanić I; Golubić Cepulić B
Acta Med Croatica; 2006 Jun; 60(3):215-25. PubMed ID: 16933834
[TBL] [Abstract][Full Text] [Related]
33. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.
Decot V; Voillard L; Latger-Cannard V; Aissi-Rothé L; Perrier P; Stoltz JF; Bensoussan D
Exp Hematol; 2010 May; 38(5):351-62. PubMed ID: 20172016
[TBL] [Abstract][Full Text] [Related]
34. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
[TBL] [Abstract][Full Text] [Related]
35. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
36. Natural killer cells differentiated in vitro from cord blood CD34
Domogala A; Blundell M; Thrasher A; Lowdell MW; Madrigal JA; Saudemont A
Cytotherapy; 2017 Jun; 19(6):710-720. PubMed ID: 28428057
[TBL] [Abstract][Full Text] [Related]
37. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice.
Cany J; van der Waart AB; Tordoir M; Franssen GM; Hangalapura BN; de Vries J; Boerman O; Schaap N; van der Voort R; Spanholtz J; Dolstra H
PLoS One; 2013; 8(6):e64384. PubMed ID: 23755121
[TBL] [Abstract][Full Text] [Related]
38. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.
Lotzová E; Savary CA; Herberman RB
J Immunol; 1987 Apr; 138(8):2718-27. PubMed ID: 3494084
[TBL] [Abstract][Full Text] [Related]
39. NK cell receptors as tools in cancer immunotherapy.
Sentman CL; Barber MA; Barber A; Zhang T
Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity of human cord blood natural killer cells is enhanced by recombinant interleukin-15.
Saghafi S; Pourfathollah AA; Kheirandish M; Azimdoust A; Behnia M; Shahjahani M; Moin M
Iran J Allergy Asthma Immunol; 2010 Jun; 9(2):69-77. PubMed ID: 20683100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
